Homologous Recombination Deficiency

Biomarker

Also known as: HRD

Related News

PARP inhibitors remain strongest in BRCA-mutant tumors as labels narrow

Apr 22, 2026

PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.

HRD Testing and Biomarker-Driven Maintenance Transform Advanced Ovarian Cancer Care

Feb 14, 2026

Homologous recombination deficiency testing and molecular profiling are reshaping treatment strategies for advanced ovarian cancer, guiding PARP inhibitor and bevacizumab maintenance decisions in newly diagnosed patients.